Key takeaways
Skyrizi (risankizumab) and Ilumya (tildrakizumab) are both injectable medications used to treat plaque psoriasis, but they have some key differences. Skyrizi is also approved for treating psoriatic arthritis and Crohn's disease, while Ilumya is only used for plaque psoriasis. Skyrizi can be administered at home after proper training, whereas a healthcare professional must give Ilumya. Skyrizi is given every 2 or 3 months depending on the condition, while Ilumya is given every 3 months after the initial doses. Both medications can increase your risk of infections and cause injection site reactions. Ilumya also causes diarrhea, while Skyrizi may cause joint pain and headaches. Additionally, Skyrizi is available in various forms, like prefilled syringes and pens, while Ilumya is only available as a brand-name medication, which may be more expensive.
